NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

November 20, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions

Lung DiseasePulmonary DiseaseAATDAlpha-1 Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency-associated Lung Disease

Interventions

BIOLOGICAL

Biological NTLA-3001

IV administration of AAV and CRISPR/Cas9 gene editing system

Trial Locations (1)

New Zealand Clinical Research, Aukland